The DOI matches its Crossref record; 24 of the 24 references it cites were found in a registry or an index.
Neurodegeneration Prevented by Lentiviral Vector Delivery of GDNF in Primate Models of Parkinson's Disease
Open accessAbstract
Lentiviral delivery of glial cell line–derived neurotrophic factor (lenti-GDNF) was tested for its trophic effects upon degenerating nigrostriatal neurons in nonhuman primate models of Parkinson's disease (PD). We injected lenti-GDNF into the striatum and substantia nigra of nonlesioned aged rhesus monkeys or young adult rhesus monkeys treated 1 week prior with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP). Extensive GDNF expression with anterograde and retrograde transport was seen in all animals. In aged monkeys, lenti-GDNF augmented dopaminergic function. In MPTP-treated monkeys, lenti-GDNF reversed functional deficits and completely prevented nigrostriatal degeneration. Additionally, lenti-GDNF injections to intact rhesus monkeys revealed long-term gene expression (8 months). In MPTP-treated monkeys, lenti-GDNF treatment reversed motor deficits in a hand-reach task. These data indicate that GDNF delivery using a lentiviral vector system can prevent nigrostriatal degeneration and induce regeneration in primate models of PD and might be a viable therapeutic strategy for PD patients.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
In Vivo Gene Delivery and Stable Transduction of Nondividing Cells by a Lentiviral Vector
Naldini, L., Blömer, U., Gallay, P., Ory, D., Mulligan, R., Gage, F. H., Verma, I. M., & Trono, D. (1996) · Science · doi:10.1126/science.272.5259.263 · Cited by 4,903
Self-citationMultiply attenuated lentiviral vector achieves efficient gene delivery in vivo
Zufferey, R., Nagy, D., Mandel, R. J., Naldini, L., & Trono, D. (1997) · Nature Biotechnology · doi:10.1038/nbt0997-871 · Cited by 1,977
Self-citationPatlak, C. S., & Blasberg, R. G. (1985) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1038/jcbfm.1985.87 · Cited by 1,673
Zufferey, R., Donello, J. E., Trono, D., & Hope, T. J. (1999) · Journal of Virology · doi:10.1128/jvi.73.4.2886-2892.1999 · Cited by 1,014
Self-citationFunctional recovery in parkinsonian monkeys treated with GDNF
Gash, D. M., Zhang, Z., Ovadia, A., Cass, W. A., Yi, A., Simmerman, L., Russell, D., Martin, D., Lapchak, P. A., Collins, F., et al. (1996) · Nature · doi:10.1038/380252a0 · Cited by 955
Dopaminergic Neurons Protected from Degeneration by GDNF Gene Therapy
Choi-Lundberg, D. L., Lin, Q., Chang, Y.-N., Chiang, Y. L., Hay, C. M., Mohajeri, H., Davidson, B. L., & Bohn, M. C. (1997) · Science · doi:10.1126/science.275.5301.838 · Cited by 625
GDNF protects nigral dopamine neurons against 6-hydroxydopamine in vivo
Kearns, C. M., & Gash, D. M. (1995) · Brain Research · doi:10.1016/0006-8993(94)01366-p · Cited by 379
Age-related declines in nigral neuronal function correlate with motor impairments in rhesus monkeys
Emborg, M. E., Ma, S. Y., Mufson, E. J., Levey, A. I., Taylor, M. D., Brown, W. D., Holden, J. E., & Kordower, J. H. (1998) · The Journal of Comparative Neurology · doi:10.1002/(sici)1096-9861(19981116)401:2<253::aid-cne7>3.0.co;2-x · Cited by 300
Self-citationDeglon, N., Tseng, J. L., Bensadoun, J.-C., Zurn, A. D., Arsenijevic, Y., Almeida, L. P. D., Zufferey, R., Trono, D., & Aebischer, P. (2000) · Human Gene Therapy · doi:10.1089/10430340050016256 · Cited by 292
Self-citationStable gene transfer to the nervous system using a non-primate lentiviral vector
Mitrophanous, K. A., Yoon, S., Rohll, J. B., Patil, D., Wilkes, F. J., Kim, V. N., Kingsman, S. M., Kingsman, A. J., & Mazarakis, N. D. (1999) · Gene Therapy · doi:10.1038/sj.gt.3301023 · Cited by 278
Cited by
Dauer, W., & Przedborski, S. (2003) · Neuron · doi:10.1016/s0896-6273(03)00568-3 · Cited by 5,469
Progress and problems with the use of viral vectors for gene therapy
Thomas, C. E., Ehrhardt, A., & Kay, M. A. (2003) · Nature Reviews Genetics · doi:10.1038/nrg1066 · Cited by 2,501
Kriks, S., Shim, J.-W., Piao, J., Ganat, Y. M., Wakeman, D. R., Xie, Z., Carrillo-Reid, L., Auyeung, G., Antonacci, C., Buch, A., et al. (2011) · Nature · doi:10.1038/nature10648 · Cited by 1,907
Self-citationThe GDNF family: Signalling, biological functions and therapeutic value
Airaksinen, M. S., & Saarma, M. (2002) · Nature Reviews Neuroscience · doi:10.1038/nrn812 · Cited by 1,828
Viral vectors for gene therapy: the art of turning infectious agents into vehicles of therapeutics
Kay, M. A., Glorioso, J. C., & Naldini, L. (2001) · Nature Medicine · doi:10.1038/83324 · Cited by 1,342
Direct brain infusion of glial cell line–derived neurotrophic factor in Parkinson disease
Gill, S. S., Patel, N. K., Hotton, G. R., O'Sullivan, K., McCarter, R., Bunnage, M., Brooks, D. J., Svendsen, C. N., & Heywood, P. (2003) · Nature Medicine · doi:10.1038/nm850 · Cited by 1,290
Lang, A. E., Gill, S., Patel, N. K., Lozano, A., Nutt, J. G., Penn, R., Brooks, D. J., Hotton, G., Moro, E., Heywood, P., et al. (2006) · Annals of Neurology · doi:10.1002/ana.20737 · Cited by 983
Ageing and neuronal vulnerability
Mattson, M. P., & Magnus, T. (2006) · Nature Reviews Neuroscience · doi:10.1038/nrn1886 · Cited by 957
The scientific and clinical basis for the treatment of Parkinson disease (2009)
Olanow, C. W., Stern, M. B., & Sethi, K. (2009) · Neurology · doi:10.1212/wnl.0b013e3181a1d44c · Cited by 908
Potential therapeutic uses of BDNF in neurological and psychiatric disorders
Nagahara, A. H., & Tuszynski, M. H. (2011) · Nature Reviews Drug Discovery · doi:10.1038/nrd3366 · Cited by 867
Obeso, J. A., Stamelou, M., Goetz, C. G., Poewe, W., Lang, A. E., Weintraub, D., Burn, D., Halliday, G. M., Bezard, E., Przedborski, S., et al. (2017) · Movement Disorders · doi:10.1002/mds.27115 · Cited by 859
“Enthusiasm for this approach then waned until the demonstration that intrastriatal gene delivery of GDNF could augment nigrostriatal function in aged monkeys and prevent the structural and functional consequences of MPTP-induced parkinsonism in nonhuman primates.(280) This led to open-label and doubleblind trials test…”
Self-citationRandomized, double-blind trial of glial cell line-derived neurotrophic factor (GDNF) in PD
Nutt, J. G., Burchiel, K. J., Comella, C. L., Jankovic, J., Lang, A. E., Laws, E. R., Lozano, A. M., Penn, R. D., Simpson, R. K., Stacy, M., et al. (2003) · Neurology · doi:10.1212/wnl.60.1.69 · Cited by 824
Toxin-induced models of Parkinson’s disease
Bové, J., Prou, D., Perier, C., & Przedborski, S. (2005) · NeuroRX · doi:10.1602/neurorx.2.3.484 · Cited by 739
An algorithm (decision tree) for the management of Parkinson’s disease (2001): Treatment Guidelines
Olanow, C. W., Watts, R. L., & Koller, W. C. (2001) · Neurology · doi:10.1212/wnl.56.suppl_5.s1 · Cited by 715
Marks, W. J., Bartus, R. T., Siffert, J., Davis, C. S., Lozano, A., Boulis, N., Vitek, J., Stacy, M., Turner, D., Verhagen, L., et al. (2010) · The Lancet Neurology · doi:10.1016/s1474-4422(10)70254-4 · Cited by 684
Self-citationLundblad, M., Andersson, M., Winkler, C., Kirik, D., Wierup, N., & Cenci, M. A. (2002) · European Journal of Neuroscience · doi:10.1046/j.0953-816x.2001.01843.x · Cited by 664
Experimental models of Parkinson's disease
Beal, M. F. (2001) · Nature Reviews Neuroscience · doi:10.1038/35072550 · Cited by 637
GENE THERAPY: Twenty-First Century Medicine
Verma, I. M., & Weitzman, M. D. (2005) · Annual Review of Biochemistry · doi:10.1146/annurev.biochem.74.050304.091637 · Cited by 616
Marks, W. J., Ostrem, J. L., Verhagen, L., Starr, P. A., Larson, P. S., Bakay, R. A., Taylor, R., Cahn-Weiner, D. A., Stoessl, A. J., Olanow, C. W., et al. (2008) · The Lancet Neurology · doi:10.1016/s1474-4422(08)70065-6 · Cited by 596
Neural stem cells display an inherent mechanism for rescuing dysfunctional neurons
Ourednik, J., Ourednik, V., Lynch, W. P., Schachner, M., & Snyder, E. Y. (2002) · Nature Biotechnology · doi:10.1038/nbt750 · Cited by 496
Millisecond-Timescale Optical Control of Neural Dynamics in the Nonhuman Primate Brain
Han, X., Qian, X., Bernstein, J. G., Zhou, H.-H., Franzesi, G. T., Stern, P., Bronson, R. T., Graybiel, A. M., Desimone, R., & Boyden, E. S. (2009) · Neuron · doi:10.1016/j.neuron.2009.03.011 · Cited by 495
Delivery of Neurotrophic Factors to the Central Nervous System: Pharmacokinetic Considerations
Thorne, R. G., & Frey, W. H. (2001) · Clinical Pharmacokinetics · doi:10.2165/00003088-200140120-00003 · Cited by 487
Lo Bianco, C., Ridet, J.-L., Schneider, B. L., Déglon, N., & Aebischer, P. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.152339799 · Cited by 482
Self-citationReversing a model of Parkinson's disease with in situ converted nigral neurons
Qian, H., Kang, X., Hu, J., Zhang, D., Liang, Z., Meng, F., Zhang, X., Xue, Y., Maimon, R., Dowdy, S. F., et al. (2020) · Nature · doi:10.1038/s41586-020-2388-4 · Cited by 480
Slevin, J. T., Gerhardt, G. A., Smith, C. D., Gash, D. M., Kryscio, R., & Young, B. (2005) · Journal of Neurosurgery · doi:10.3171/jns.2005.102.2.0216 · Cited by 475
Delivery of bioactive molecules into the cell: the Trojan horse approach
Dietz, G. P. H., & Bähr, M. (2004) · Molecular and Cellular Neuroscience · doi:10.1016/j.mcn.2004.03.005 · Cited by 469
Palfi, S., Gurruchaga, J. M., Ralph, G. S., Lepetit, H., Lavisse, S., Buttery, P. C., Watts, C., Miskin, J., Kelleher, M., Deeley, S., et al. (2014) · The Lancet · doi:10.1016/s0140-6736(13)61939-x · Cited by 450
Self-citationPardridge, W. M. (2007) · Pharmaceutical Research · doi:10.1007/s11095-007-9324-2 · Cited by 447
Borlongan, C. V., Hadman, M., Davis Sanberg, C., & Sanberg, P. R. (2004) · Stroke · doi:10.1161/01.str.0000141680.49960.d7 · Cited by 439
Ghosh, A., Roy, A., Liu, X., Kordower, J. H., Mufson, E. J., Hartley, D. M., Ghosh, S., Mosley, R. L., Gendelman, H. E., & Pahan, K. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0704908104 · Cited by 438
Self-citationMazarakis, N. D. (2001) · Human Molecular Genetics · doi:10.1093/hmg/10.19.2109 · Cited by 426
The aging brain: morphomolecular senescence of cortical circuits
Hof, P. R., & Morrison, J. H. (2004) · Trends in Neurosciences · doi:10.1016/j.tins.2004.07.013 · Cited by 411
Neuroinflammation, oxidative stress, and the pathogenesis of Parkinson’s disease
Lee Mosley, R., Benner, E. J., Kadiu, I., Thomas, M., Boska, M. D., Hasan, K., Laurie, C., & Gendelman, H. E. (2006) · Clinical Neuroscience Research · doi:10.1016/j.cnr.2006.09.006 · Cited by 387
The Neurotrophin Family of Neurotrophic Factors: An Overview
Skaper, S. D. (2012) · Methods in Molecular Biology · doi:10.1007/978-1-61779-536-7_1 · Cited by 372
Cellular pathology of Parkinson?s disease: astrocytes, microglia and inflammation
Teismann, P., & Schulz, J. B. (2004) · Cell and Tissue Research · doi:10.1007/s00441-004-0944-0 · Cited by 363
Gene delivery by lentivirus vectors
Cockrell, A. S., & Kafri, T. (2007) · Molecular Biotechnology · doi:10.1007/s12033-007-0010-8 · Cited by 355
A versatile tool for conditional gene expression and knockdown
Szulc, J., Wiznerowicz, M., Sauvain, M.-O., Trono, D., & Aebischer, P. (2006) · Nature Methods · doi:10.1038/nmeth846 · Cited by 351
Self-citation326. A Versatile Tool for Conditional Gene Expression and Knockdown
Szulc, J., Wiznerowicz, M., Beermann, F., Trono, D., & Aebischer, P. (2006) · Molecular Therapy · doi:10.1016/j.ymthe.2006.08.383 · Cited by 350
Self-citationde Boer, A. G., & Gaillard, P. J. (2007) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.47.120505.105237 · Cited by 348
Redmond, D. E., Bjugstad, K. B., Teng, Y. D., Ourednik, V., Ourednik, J., Wakeman, D. R., Parsons, X. H., Gonzalez, R., Blanchard, B. C., Kim, S. U., et al. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0704091104 · Cited by 344
Thoenen, H., & Sendtner, M. (2002) · Nature Neuroscience · doi:10.1038/nn938 · Cited by 336
“Although (unregulated) overexpression of neurotrophic molecules by viral vectors has already provided encouraging result”
BackgroundAbsolute requirement of GDNF for adult catecholaminergic neuron survival
Pascual, A., Hidalgo-Figueroa, M., Piruat, J. I., Pintado, C. O., Gómez-Díaz, R., & López-Barneo, J. (2008) · Nature Neuroscience · doi:10.1038/nn.2136 · Cited by 334
The role of glial cells in Parkinsonʼs disease
Vila, M., Jackson-Lewis, V., Guégan, C., Chu Wu, D., Teismann, P., Choi, D.-K., Tieu, K., & Przedborski, S. (2001) · Current Opinion in Neurology · doi:10.1097/00019052-200108000-00009 · Cited by 326
Viral vectors for gene delivery to the nervous system
Davidson, B. L., & Breakefield, X. O. (2003) · Nature Reviews Neuroscience · doi:10.1038/nrn1104 · Cited by 321
Therapeutic immunization protects dopaminergic neurons in a mouse model of Parkinson's disease
Benner, E. J., Mosley, R. L., Destache, C. J., Lewis, T. B., Jackson-Lewis, V., Gorantla, S., Nemachek, C., Green, S. R., Przedborski, S., & Gendelman, H. E. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0400569101 · Cited by 321
Hadaczek, P., Yamashita, Y., Mirek, H., Tamas, L., Bohn, M. C., Noble, C., Park, J. W., & Bankiewicz, K. (2006) · Molecular Therapy · doi:10.1016/j.ymthe.2006.02.018 · Cited by 312
Transgenic Monkeys Produced by Retroviral Gene Transfer into Mature Oocytes
Chan, A. W. S., Chong, K. Y., Martinovich, C., Simerly, C., & Schatten, G. (2001) · Science · doi:10.1126/science.291.5502.309 · Cited by 312
How to make a midbrain dopaminergic neuron
Arenas, E., Denham, M., & Villaescusa, J. C. (2015) · Development · doi:10.1242/dev.097394 · Cited by 308
Åkerud, P., Canals, J. M., Snyder, E. Y., & Arenas, E. (2001) · The Journal of Neuroscience · doi:10.1523/jneurosci.21-20-08108.2001 · Cited by 305
Novel pharmacological targets for the treatment of Parkinson's disease
Schapira, A. H. V., Bezard, E., Brotchie, J., Calon, F., Collingridge, G. L., Ferger, B., Hengerer, B., Hirsch, E., Jenner, P., Novère, N. L., et al. (2006) · Nature Reviews Drug Discovery · doi:10.1038/nrd2087 · Cited by 298
Localized striatal delivery of GDNF as a treatment for Parkinson disease
Kirik, D., Georgievska, B., & Björklund, A. (2004) · Nature Neuroscience · doi:10.1038/nn1175 · Cited by 290
α-Synuclein–Induced Down-Regulation of Nurr1 Disrupts GDNF Signaling in Nigral Dopamine Neurons
Decressac, M., Kadkhodaei, B., Mattsson, B., Laguna, A., Perlmann, T., & Björklund, A. (2012) · Science Translational Medicine · doi:10.1126/scitranslmed.3004676 · Cited by 290
Therapeutic strategies for Parkinson disease: beyond dopaminergic drugs
Charvin, D., Medori, R., Hauser, R. A., & Rascol, O. (2018) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2018.136 · Cited by 287
Warren Olanow, C., Bartus, R. T., Baumann, T. L., Factor, S., Boulis, N., Stacy, M., Turner, D. A., Marks, W., Larson, P., Starr, P. A., et al. (2015) · Annals of Neurology · doi:10.1002/ana.24436 · Cited by 287
Self-citationLentiviral-Mediated RNA Interference
Abbas-Terki, T., Blanco-Bose, W., Déglon, N., Pralong, W., & Aebischer, P. (2002) · Human Gene Therapy · doi:10.1089/104303402320987888 · Cited by 284
Self-citationGrondin, R., Zhang, Z., Yi, A., Cass, W. A., Maswood, N., Andersen, A. H., Elsberry, D. D., Klein, M. C., Gerhardt, G. A., & Gash, D. M. (2002) · Brain · doi:10.1093/brain/awf234 · Cited by 283
Thiruchelvam, M., McCormack, A., Richfield, E. K., Baggs, R. B., Tank, A. W., Di Monte, D. A., & Cory‐Slechta, D. A. (2003) · European Journal of Neuroscience · doi:10.1046/j.1460-9568.2003.02781.x · Cited by 280
Delivery of peptide and protein drugs over the blood–brain barrier
Brasnjevic, I., Steinbusch, H. W. M., Schmitz, C., & Martinez-Martinez, P. (2009) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2008.12.002 · Cited by 279
Pathogenic role of glial cells in Parkinson's disease
Teismann, P., Tieu, K., Cohen, O., Choi, D., Wu, D. C., Marks, D., Vila, M., Jackson‐Lewis, V., & Przedborski, S. (2003) · Movement Disorders · doi:10.1002/mds.10332 · Cited by 275
GDNF Delivery Using Human Neural Progenitor Cells in a Rat Model of ALS
Klein, S. M., Behrstock, S., McHugh, J., Hoffmann, K., Wallace, K., Suzuki, M., Aebischer, P., & Svendsen, C. N. (2005) · Human Gene Therapy · doi:10.1089/hum.2005.16.509 · Cited by 265
Self-citationGene Therapy with Viral Vectors
Kootstra, N. A., & Verma, I. M. (2003) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.43.100901.140257 · Cited by 267
Wang, L.-J., Lu, Y.-Y., Muramatsu, S.-I., Ikeguchi, K., Fujimoto, K.-I., Okada, T., Mizukami, H., Matsushita, T., Hanazono, Y., Kume, A., et al. (2002) · The Journal of Neuroscience · doi:10.1523/jneurosci.22-16-06920.2002 · Cited by 262
Point source concentration of GDNF may explain failure of phase II clinical trial
SALVATORE, M., AI, Y., FISCHER, B., ZHANG, A., GRONDIN, R., ZHANG, Z., GERHARDT, G., & GASH, D. (2006) · Experimental Neurology · doi:10.1016/j.expneurol.2006.07.015 · Cited by 260
Neurodegeneration and neuroprotection in Parkinson disease
Fahn, S., & Sulzer, D. (2004) · NeuroRX · doi:10.1602/neurorx.1.1.139 · Cited by 257
Selective loss of dopaminergic neurons in the substantia nigra of Pitx3-deficient aphakia mice
Hwang, D. (2003) · Molecular Brain Research · doi:10.1016/s0169-328x(03)00162-1 · Cited by 257
Kordower, J. H., Herzog, C. D., Dass, B., Bakay, R. A. E., Stansell, J., Gasmi, M., & Bartus, R. T. (2006) · Annals of Neurology · doi:10.1002/ana.21032 · Cited by 252
Self-citationPeden, C. S., Burger, C., Muzyczka, N., & Mandel, R. J. (2004) · Journal of Virology · doi:10.1128/jvi.78.12.6344-6359.2004 · Cited by 222
Gene Therapy for Neurodegenerative Diseases
Sudhakar, V., & Richardson, R. M. (2019) · Neurotherapeutics · doi:10.1007/s13311-018-00694-0 · Cited by 212
Zhang, Y., Calon, F., Zhu, C., Boado, R. J., & Pardridge, W. M. (2003) · Human Gene Therapy · doi:10.1089/10430340360464660 · Cited by 194
Lentiviral Vector Gene Transfer of Endostatin/Angiostatin for Macular Degeneration (GEM) Study
Campochiaro, P. A., Lauer, A. K., Sohn, E. H., Mir, T. A., Naylor, S., Anderton, M. C., Kelleher, M., Harrop, R., Ellis, S., & Mitrophanous, K. A. (2017) · Human Gene Therapy · doi:10.1089/hum.2016.117 · Cited by 186
Dopamine Gene Therapy for Parkinson’s Disease in a Nonhuman Primate Without Associated Dyskinesia
Jarraya, B., Boulet, S., Scott Ralph, G., Jan, C., Bonvento, G., Azzouz, M., Miskin, J. E., Shin, M., Delzescaux, T., Drouot, X., et al. (2009) · Science Translational Medicine · doi:10.1126/scitranslmed.3000130 · Cited by 186
Self-citationZhang, L., Zhang, L., Li, L., & Hölscher, C. (2019) · Journal of Parkinson's Disease · doi:10.3233/jpd-181503 · Cited by 173
Ji, B., Maeda, J., Sawada, M., Ono, M., Okauchi, T., Inaji, M., Zhang, M.-R., Suzuki, K., Ando, K., Staufenbiel, M., et al. (2008) · The Journal of Neuroscience · doi:10.1523/jneurosci.2312-08.2008 · Cited by 169
Sun, M., Kong, L., Wang, X., Lu, X.-G., Gao, Q., & Geller, A. I. (2005) · Brain Research · doi:10.1016/j.brainres.2005.05.072 · Cited by 154
Baekelandt, V, Eggermont, K., Michiels, M., Nuttin, B., & Debyser, Z. (2003) · Gene Therapy · doi:10.1038/sj.gt.3302094 · Cited by 153
Advances in small molecules promoting neurotrophic function
PRICE, R., MILNE, S., SHARKEY, J., & MATSUOKA, N. (2007) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2007.03.005 · Cited by 148
Effective GDNF brain delivery using microspheres—A promising strategy for Parkinson's disease
Garbayo, E., Montero-Menei, C. N., Ansorena, E., Lanciego, J. L., Aymerich, M. S., & Blanco-Prieto, M. J. (2009) · Journal of Controlled Release · doi:10.1016/j.jconrel.2008.12.010 · Cited by 150
“Another feasible option is the use of gene therapy using different strains of modified viruses carrying the GDNF gene [9–11].”
Challenges and opportunities in CNS delivery of therapeutics for neurodegenerative diseases
Barchet, T. M., & Amiji, M. M. (2009) · Expert Opinion on Drug Delivery · doi:10.1517/17425240902758188 · Cited by 145
Stable RNA interference: Comparison of U6 and H1 promoters in endothelial cells and in mouse brain
Mäkinen, P. I., Koponen, J. K., Kärkkäinen, A., Malm, T. M., Pulkkinen, K. H., Koistinaho, J., Turunen, M. P., & Ylä‐Herttuala, S. (2006) · The Journal of Gene Medicine · doi:10.1002/jgm.860 · Cited by 134
CHEN, Y., AI, Y., SLEVIN, J., MALEY, B., & GASH, D. (2005) · Experimental Neurology · doi:10.1016/j.expneurol.2005.07.010 · Cited by 126
Methods for Gene Transfer to the Central Nervous System
Kantor, B., Bailey, R. M., Wimberly, K., Kalburgi, S. N., & Gray, S. J. (2014) · Advances in Genetics · doi:10.1016/b978-0-12-800149-3.00003-2 · Cited by 109
Kim, S. R., Kareva, T., Yarygina, O., Kholodilov, N., & Burke, R. E. (2012) · Molecular Therapy · doi:10.1038/mt.2011.213 · Cited by 107
Fluoxetine rescues impaired hippocampal neurogenesis in a transgenic A53T synuclein mouse model
Kohl, Z., Winner, B., Ubhi, K., Rockenstein, E., Mante, M., Münch, M., Barlow, C., Carter, T., Masliah, E., & Winkler, J. (2012) · European Journal of Neuroscience · doi:10.1111/j.1460-9568.2011.07933.x · Cited by 101
Chu, Y., Bartus, R. T., Manfredsson, F. P., Olanow, C. W., & Kordower, J. H. (2020) · Brain · doi:10.1093/brain/awaa020 · Cited by 88
Self-citationNeurogenesis in adult primates
Rakic, P. (2002) · Progress in Brain Research · doi:10.1016/s0079-6123(02)38067-1 · Cited by 77
Targeting the Progression of Parkinsons Disease
George, J., Mok, S., Moses, D., Wilkins, S., Bush, A., Cherny, R., & Finkelstein, D. (2009) · Current Neuropharmacology · doi:10.2174/157015909787602814 · Cited by 77
Herzog, C. D., Dass, B., Gasmi, M., Bakay, R., Stansell, J. E., Tuszynski, M., Bankiewicz, K., Chen, E.-Y., Chu, Y., Bishop, K., et al. (2008) · Molecular Therapy · doi:10.1038/mt.2008.170 · Cited by 72
Self-citationTrophic factors therapy in Parkinson's disease
Ramaswamy, S., Soderstrom, K. E., & Kordower, J. H. (2009) · Progress in Brain Research · doi:10.1016/s0079-6123(09)17514-3 · Cited by 72
Self-citationMarchionini, D. M., Lehrmann, E., Chu, Y., He, B., Sortwell, C. E., Becker, K. G., Freed, W. J., Kordower, J. H., & Collier, T. J. (2007) · Brain Research · doi:10.1016/j.brainres.2007.02.028 · Cited by 69
Self-citationPeng, J., Liu, Q., Rao, M. S., & Zeng, X. (2013) · SLAS Discovery · doi:10.1177/1087057112474468 · Cited by 64
In vivo optogenetic control of striatal and thalamic neurons in non-human primates
Galvan, A., Hu, X., Smith, Y., & Wichmann, T. (2012) · PLoS ONE · doi:10.1371/journal.pone.0050808 · Cited by 45
“Lentiviral vectors were found to be safe and effective when delivered in basal ganglia regions in previous macaque studies (e.g. [51,52] ).”
BackgroundChtarto, A., Humbert-Claude, M., Bockstael, O., Das, A. T., Boutry, S., Breger, L. S., Klaver, B., Melas, C., Barroso-Chinea, P., Gonzalez-Hernandez, T., et al. (2016) · Molecular Therapy - Methods & Clinical Development · doi:10.1038/mtm.2016.27 · Cited by 43
Physical positioning markedly enhances brain transduction after intrathecal AAV9 infusion
Castle, M. J., Cheng, Y., Asokan, A., & Tuszynski, M. H. (2018) · Science Advances · doi:10.1126/sciadv.aau9859 · Cited by 41
Herzog, C. D., Bishop, K. M., Brown, L., Wilson, A., Kordower, J. H., & Bartus, R. T. (2011) · Drug Delivery and Translational Research · doi:10.1007/s13346-011-0037-z · Cited by 29
Self-citation
Metadata
- Authors
- Kordower, J. H., Emborg, M. E., Bloch, J., Ma, S. Y., Chu, Y., Leventhal, L., McBride, J., Chen, E.-Y., Palfi, S., Roitberg, B. Z., Brown, W. D., Holden, J. E., Pyzalski, R., Taylor, M. D., Carvey, P., Ling, Z., Trono, D., Hantraye, P., Déglon, N., & Aebischer, P.
- Venue
- Science
- Published
- 2000-10-27
- Volume
- 290
- Issue
- 5492
- Pages
- 767-773
- ISSN
- 0036-8075 (ISSN-L)
- 1095-9203
- OpenAlex
- W2108724455
- Cited by
- 1,251
- References
- 24
- FWCI
- 54.21
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.